诺泰生物（688076）被处罚，股民索赔可期

Core Viewpoint - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. (Nuotai Biopharma) has been found guilty of falsifying financial statements and providing misleading information in its public offerings, leading to administrative penalties from the China Securities Regulatory Commission (CSRC) [1][3][9]. Group 1: Financial Misconduct - Nuotai Biopharma's 2021 annual report contained false records, including a reported revenue of 30 million yuan from a technology transfer to Zhejiang Huabei Pharmaceutical, which lacked the financial capability to pay for the transaction [1][7]. - The technology transfer was deemed to lack commercial substance, resulting in an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the total profit reported for that period [1][7]. Group 2: Public Offering Irregularities - Nuotai Biopharma fabricated significant false content in its public offering documents, particularly in the financial accounting information section of its bond issuance prospectus [2][8]. - The company issued convertible bonds totaling 434 million yuan, with the issuance process and financial data being compromised due to the previously mentioned inflated figures [2][8]. Group 3: Regulatory Actions and Legal Implications - The CSRC has mandated corrections, issued warnings, and imposed fines on Nuotai Biopharma and its actual controller Zhao Dezhong, along with other responsible personnel [3][9]. - Affected investors are encouraged to register for compensation claims, as they may pursue civil litigation for damages resulting from the company's misleading statements [3][10].